Darunavir / Cobicistat

U.S. Brand Name

Prezcobix

Abbreviation(s)

DRV/COBI

First U.S. Approval

January 31, 2015

Component ARVs

NRTI Based?

No

One Dose Daily?

Yes

Single Tablet Regimen

No

U.S. FDA Label

Prezcobix Label

U.S. Manufacturer

Other Reference Links

Clinical Info HIV Drug Database

National HIV Curriculum

Formulations

Strength	Image	Description	Boosted
800 mg darunavir + 150 mg cobicistat	X	pink, oval-shaped, film-coated tablets debossed with "800" on one side and "TG"	No

Adult dosing

Dosage	Formulation	Population/Notes
One tablet taken once daily with food	Film-Coated Tablets	Patients weighing at least 40 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V). Not recommended during pregnancy.

Pediatric dosing

film-coated, 40 kg or greater

References

Assistance Programs

Janssen Care Path

Displaying 1 - 3 of 3

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Lenacapavir Darunavir/cobicistat	Green: Administer standard doses	Administer standard doses	No clinically significant effect expected	AUC increased 94%; Cmax increased 130%	800/150 mg once daily (in fed state)	Not reported
Maraviroc DRV/c 48	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc					Reduce dose of maraviroc to 150 mg BID
Fostemsavir DRV/c 11	Green: Administer standard doses	Administer standard doses		Temsavir Cmax increased 79%, AUC increased 97%, Cmin increased 124%	800 / 150 mg once daily	Not studied

Subscribe to Darunavir / Cobicistat